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Abstract 
Review on CD74, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: DHLAG, HLADG, II, Ia-GAMMA 
HGNC (Hugo): CD74 
Location: 5q32 
DNA/RNA 
Description 
The CD74 gene consists of 9 exons, different 
transcripts results in four protein variants. 
Transcription 
CD74 gene is processed into 4 different in-vivo 
know transcripts resulting from two different 
translation initiation sites and alternative splicing 
(Borghese and Clanchy, 2011; UniProt Consortium, 
2013): 
P43 - The longest isoform. Contains a longer 
cytoplasmic tail due to the use of an alternative 
translation initiation site, and a THY domain from 
alternative splicing. 
P41 - Similar to the P43 isoform but does not 
contain the longer cytoplasmic tail. 
P35 - Similar to the P43 isoform but does not 
contain the THY domain. 
P33 - Does not contain not the longer cytoplasmic 
tail and not the THY domain. 
 
Transcript structure of human CD74 (Geer et al., 2010). 
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Schematic representation of a monomeric CD74, isoform p33. 
 
 
Protein 
Description 
CD74 is a non-polymorphic type II integral 
membrane protein. The most common isoform is 
p33, which is 296 aa long and has a molecular 
weight of 33 kDa. The protein consists of three 
parts, a 46 aa long N-terminus cytoplasmic tail, 26 
aa long transmembranal domain and a 224 aa long 
luminal region. CD74 assembles to homotrimers 
immediately after synthesis. 
Expression 
CD74 is mainly expressed in antigen presenting 
cells, endothelial cells and neuroglia cells. 
Localisation 
Trimers of CD74 are expressed in the endoplasmic 
reticulum (ER), in association with MHC α and β 
chains. The complex is transported to the trans-
Golgi and then diverted from the secretory pathway 
to the endocytic system and ultimately to acidic 
endosome or lysosome-like structures called MHC 
class II compartments (MIIC or CIIV). A small 
proportion of CD74 is modified by the addition of 
chondroitin sulfate (CD74-CS), and this form of 
CD74 is expressed on the cell surface (Stumptner-
Cuvelette and Benaroch, 2002). 
Function 
CD74 function has two main functions: 
1) MHCII chaperon  
MHC class II molecules are heterodimeric 
complexes that present foreign antigenic peptides 
on the cell surface of antigen-presenting cells 
(APCs) to CD4+ T cells. MHC class II synthesis 
and assembly begins in the endoplasmic reticulum 
(ER) with the non-covalent association of the MHC 
α and β chains with trimers of CD74. Three MHC 
class II α β dimers bind sequentially to a trimer of 
the CD74 to form a nonameric complex (αβCD74)3, 
which then exits the ER (Roche et al., 1991). After 
being transported to the trans-Golgi, the αβCD74 
complex is diverted from the secretory pathway to 
the endocytic compartments. Once in the endocytic 
compartments, CD74 is proteolytically processed. 
CD74 lumenal domain undergoes a stepwise 
proteolytic cleavage, which results in a short class 
II-associated Ii chain peptide (CLIP), which 
remains in the MHC class II peptide grove (Neefjes 
et al., 1990; Roche and Cresswell, 1991; 
Stumptner-Cuvelette and Benaroch, 2002). The 
final step for MHC class II expression requires 
interaction of αβCLIP complexes with another class 
II-related αβ dimer, called HLA-DM. Binding of 
this molecule excludes the residual CLIP peptide, 
rendering the αβ dimers ultimately competent to 
bind antigenic peptides, which are mainly derived 
from internalized antigens and also are delivered to 
the endocytic pathway (Denzin and Cresswell, 
1995; Ghosh et al., 1995). Thus, CD74 was thought 
to function mainly as MHC class II chaperone, 
which promotes ER exit of MHC class II 
molecules, directs them to endocytic compartments, 
prevents self-peptide binding in the ER and 
contributes to peptide editing in the MHC class II 
compartment (Matza et al., 2003). 
2) CD74 as cell surface receptor 
A small proportion of CD74 is modified by the 
addition of chondroitin sulfate (CD74-CS), and this 
form of CD74 is expressed on the cell surface 
(Matza et al., 2003; Naujokas et al., 1993). This cell 
surface expression of CD74 is not strictly 
dependent on class II MHC (Henne et al., 1995; 
Starlets et al., 2006), and numerous non-class II 
positive cells express CD74 where it can serve as a 
receptor for the initiation of different signaling 
cascades (Maharshak et al., 2010; Stumptner-
Cuvelette and Benaroch, 2002). The cytokine, 
macrophage migration inhibitory factor (MIF), was 
found to be the natural ligand of CD74. MIF binds 
to the extracellular domain of CD74 with high 
affinity (KD = 1.40 × 10-9 M) and initiates a 
signaling cascade (Leng et al., 2003). CD74 forms a 
complex with CD44, which is essential for the 
MIF-induced signaling cascade (Gore et al., 2008; 
Shi et al., 2006). 
In murine B cells, CD74 expression is directly 
involved in shaping the B cell repertoire by 
regulating mature B cell survival (Gore et al., 2008; 
Matza et al., 2003; Shachar and Flavell, 1996; 
Starlets et al., 2006). MIF binding to CD74 induces 
a signaling pathway that involves the Syk tyrosine 
kinase and the PI3K/Akt pathway (Gore et al., 
2008; Starlets et al., 2006), induction of CD74 
intramembrane cleavage, and the release of the 
CD74 intracellular domain (CD74-ICD) (Matza et 
al., 2002; Schneppenheim et al., 2013). CD74-ICD 
translocates to the nucleus where it induces 
activation of transcription mediated by the NF-κB 
p65/RelA homodimer and its co-activator, 
TAFII105, resulting in regulation of transcription of 
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genes that control B cell proliferation and survival 
(Gore et al., 2008; Matza et al., 2001; Starlets et al., 
2006). MIF was found to regulate cell entry into the 
S-phase in a CD74 and CD44-dependent fashion, 
by elevating cyclin E levels, resulting in cell 
proliferation. In addition, this cascade augments 
Bcl-2 expression, further supporting cell survival 
(Cohen et al., 2012; Gordin et al., 2010; Gore et al., 
2008; Lantner et al., 2007; Sapoznikov et al., 2008; 
Starlets et al., 2006). Thus, the MIF binding to 
CD74/CD44 complex initiates a pathway, resulting 
in proliferation of the mature B cell population, and 
their rescue from death. 
Implicated in 
Chronic lymphocytic leukaemia (CLL) 
Prognosis 
CD74 and its ligand, MIF, were shown to play a 
pivotal role in the regulation of CLL cell survival. 
CLL cells markedly upregulate both expression of 
their cell surface CD74, and their MIF production. 
Stimulation of CD74 with the MIF ligand (as well 
as with an agonistic antibody) initiates a signaling 
cascade leading to IL-8 transcription and secretion 
in all CLL cells, regardless of the clinical status of 
the patients. Secreted IL-8 induces the transcription 
and translation of the anti-apoptotic protein, Bcl-2, 
and thus regulates an anti-apoptotic pathway. 
Blocking of CD74 (by milatuzumab), or of MIF or 
IL-8 results in dramatic downregulation of Bcl-2 
expression, and augmentation of apoptosis (Binsky 
et al., 2007). 
In addition, stimulation of CD74 with its natural 
ligand, MIF, initiates a signaling cascade that 
results in upregulation of TAp63, which directly 
regulates CLL survival. TAp63 expression also 
elevates the expression of the integrin VLA-4, 
particularly during the advanced stage of the 
disease. Blocking of CD74, TAp63, or VLA-4 
inhibits the in vivo homing of CLL cells to the bone 
marrow (BM). Thus, CD74 and its target genes 
TAp63 and VLA-4 facilitate migration of CLL cells 
back to the BM, where they interact with the 
supportive BM environment that rescues them from 
apoptosis (Binsky et al., 2010). 
Multiple myeloma (MM) 
Prognosis 
CD74 expression was observed in 19 of 22 cases of 
multiple myeloma, with most expressing moderate 
to high levels in the majority of malignant plasma 
cells (Burton et al., 2004). CD74, expressed in MM, 
was evaluated as a target for immunotherapy with 
milatuzumab (a humanized anti-CD74 antibody). In 
a multicentre dose escalation study, 25 patients with 
advanced MM received milatuzumab doses of 1.5 
(N = 8), 4.0 (N = 9), 8.0 (N = 4) or 16.0 mg/kg (N = 
4) administered twice weekly x 4. 
 
CD74 activation by MIF up regulates cell survival and VLA-
4 expression. 
 
They had a median of 5 prior treatments (17 post ≥ 
1 stem cell transplantation) and were refractory (N 
= 7) or relapsed (N = 18) with generally short-lived 
responses to last treatment (median 4.0 months). 
After increasing prophylactic medications and 
slowing administration, infusions were well 
tolerated (National Cancer Institute-Common 
Terminology Criteria v3 toxicity Grades 1-2) with 
no dose-limiting toxicity at higher doses. Only one 
patient developed borderline positive human anti-
milatuzumab antibody titres of uncertain clinical 
significance. Although milatuzumab was rapidly 
cleared from circulation with little serum 
accumulation and low trough levels, B-cell levels 
were moderately decreased with treatment (median 
decrease, 34%). Disease stabilization and evidence 
of pharmacodynamic activity support further 
development for use in combination with other 
agents or as a drug conjugate (Kaufman et al., 
2013). 
Mantle cell lymphoma (MCL) 
Prognosis 
CD74 is expressed on MCL. The combination of 
milatuzumab and rituximab has preclinical in vitro 
and in vivo activity in MCL (Alinari et al., 2011). 
Treatment of MCL cell lines and primary patient 
tumor cells with immobilized milatuzumab resulted 
in statistically significant enhanced cell death 
(Alinari et al., 2012). 
Non-Hodgkin lymphoma (NHL) 
Prognosis 
Preclinical studies of the humanized anti-CD74 
mAb hLL1 have shown that it is an effective 
therapeutic agent that may be of significant value 
for treatment of NHL (Stein et al., 2007). 
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Schematic representation of the potential mechanisms by which CD74 is involved in MCP-1. induction. 
 
Invasive carcinoma of the bladder 
Prognosis 
CD74 expression is increased in high-grade, 
invasive carcinoma of the bladder.  
Its expression was significantly associated with 
older age at diagnosis (Choi et al., 2013). 
Gastrointestinal carcinoma 
Prognosis 
Expression of CD74 within gastrointestinal 
carcinomas showed a statistically greater expression 
than in the normal tissue counterparts. CD74 
expression was observed in 95% of pancreatic 
carcinomas with the majority of cases presenting a 
mostly intense, diffuse labeling pattern.  
The results suggested a trend towards greater 
expression within the higher-grade carcinomas. 
Colorectal and gastric carcinomas gave similar 
results with 60% and 86%, respectively, positive 
for CD74 with an intense, diffuse staining pattern. 
For PanIN lesions there was greater expression of 
CD74 within higher grade, PanIN-3 lesions, 
whereas the colonic adenomas showed no such 
trend, but overall, a higher frequency and intensity 
of CD74 labeling than was observed within the 
colon carcinomas. These findings are supportive of 
a role for CD74 in the development and 
maintenance of gastrointestinal neo-plasia, and 
provide a rationale for development of therapeutic 
agents that are able to block CD74 function, 
specifically within the tumor cell (Gold et al., 
2010). 
Non-small cell lung cancer 
Prognosis 
CD74 was found to be expressed on non-small cell 
lung cancer (NSCLC) cells (Ioachim et al., 1996). 
CD74 immunoreactivity was present in the stromal 
cells in most tumors.  
However, in many tumors the malignant cells 
themselves also strongly expressed CD74 
(McClelland et al., 2009). 
Thymic epithelial neoplasms 
Prognosis 
Sixty-four thymic epithelial neoplasms (27 cases of 
benign thymoma, 20 cases of invasive thymoma, 
and 17 cases of true thymic carcinoma) were 
studied for neoplastic epithelial cell expression of 
CD74 and MHC class II molecules by 
immunohistochemical staining of paraffin-
embedded tissue.  
Neoplastic epithelial cells in 88% of thymic 
carcinomas (15/17), 70% of invasive thymomas 
(14/20), but only 33% of benign thymomas (9/27) 
were immunoreactive for CD74. 
 A subset of CD74-positive neoplasms was positive 
for MHC class II as well, with higher relative rates 
of dual positivity in more aggressive neoplasms. In 
addition, specific histologic subtypes of thymic 
epithelial neoplasms displayed differing patterns of 
CD74 positivity. Based on these findings, CD74 
and MHC class II are useful markers for the 
classification of thymic epithelial neoplasms (Datta 
et al., 2000). 
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Pancreatic cancer 
Prognosis 
Pancreatic ductal adenocarcinoma (PDAC) is still 
one of the most fatal cancers. Sixty-eight patients 
receiving curative extended resection combined 
with preoperative chemoradiation and postoperative 
chemotherapy for primary PDAC were selected. 
Immunohistochemistry using anti-CD74 antibody 
on paraffin-embedded tissue samples was 
performed, and cases were divided into two groups 
according to the ratio of CD74-positive cells: 
expression level I, CD74-positive cells or=70%. 
The correlation of CD74 expression level with 
clinicopathological features and overall survival 
was evaluated. Forty-seven (69.1%) and 21 (30.9%) 
patients showed level I and II CD74 expression, 
respectively. Patients with level I CD74 expression 
had a significantly better survival rate than those 
with level II (P = 0.003). Among the patients with 
pathological tumor-node-metastasis stages I and II, 
those with level I CD74 expression showed a 
significantly better prognosis than those with level 
II (P = 0.006). CD74 expression proved as a useful 
prognostic indicator for PDAC treated with 
multimodal therapy (Nagata et al., 2009). 
Atherosclerosis 
Prognosis 
Overexpression of CD74 has been reported in 
atherosclerotic plaques. Stimulation of CD74 with 
an anti-CD74 antibody, which binds the CD74 
extracellular domain, induces the expression of the 
NF-κB-regulated gene MCP-1, a small cytokine 
that belongs to the CC chemokine family. MCP-1 
recruits monocytes, memory T cells, and dendritic 
cells to the sites of inflammation (Martín-Ventura 
et al., 2009). 
Alzheimer 
Prognosis 
CD74 has been found to be upregulated in the 
microglia and neurons of Alzheimer's patients and 
can interact with the amyloid precursor protein, 
potentially inhibiting the production of amyloid-β. 
HIV 
Prognosis 
HIV-1 gp41 binds directly to CD74 in HIV-1-
infected cells, leading to ERK1/ERK2 MAPK 
activation and enhanced HIV-1 infection (Zhou et 
al., 2011). The cytoplasmic region of HIV-1 Vpu 
also was found to interact with the 30-amino-acid 
cytoplasmic tail of CD74. Human monocytic U937 
cells infected with wild-type or Vpu-defective HIV-
1 showed that Vpu down-regulated the surface 
expression of MHC class II molecules (Hussain et 
al., 2008). 
Gastric ulceration 
Prognosis 
The pathogenic bacterium, Helicobacter pylori, was 
shown to bind to CD74 on gastric epithelial cells. 
Upon H. pylori binding to CD74, NF-κB activation 
occurs resulting in the production of 
proinflammatory cytokines, including IL-8. IL-8 
plays a major role in the proinflammatory immune 
response to H. pylori infection, and the interaction 
of H. pylori with the gastric epithelial cells might 
be of critical importance in the immune response to 
this infection and the development of gastric 
ulceration (Beswick et al., 2005). 
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